Artur Schmidtchen
Corporate Officer/Principal bij University of Lund
Actieve functies van Artur Schmidtchen
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| University of Lund | Corporate Officer/Principal | - | - |
Loopbaan van Artur Schmidtchen
Eerdere bekende functies van Artur Schmidtchen
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Sista versen 26366 AB
 Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Oprichter | 26-10-2009 | - |
DermaGen AB
 DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden. | Directeur/Bestuurslid | 01-05-2004 | - |
| Oprichter | 20-07-2011 | - |
Statistieken
Internationaal
| Zweden | 4 |
Operationeel
| Founder | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
DermaGen AB
DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden. | Health Technology |
Sista versen 26366 AB
Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Health Technology |
- Beurs
- Insiders
- Artur Schmidtchen
- Ervaring
